Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Mulleman

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Scandinavian Journal of Rheumatology|February 6, 2010
Trough infliximab concentration may predict long-term maintenance of infliximab in ankylosing spondylitisD Chu Miow Lin, D Mulleman, N Azzopardi, et al.
Scandinavian Journal of Rheumatology|April 22, 2016
Diagnostic delay of pyogenic vertebral osteomyelitis and its associated factorsM Jean, J-O Irisson, G Gras, et al.
Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society|February 21, 2013
Early decrease of serum biomarkers of type II collagen degradation (Coll2-1) and joint inflammation (Coll2-1 NO₂ ) by hyaluronic acid intra-articular injections in patients with knee osteoarthritis: a research study part of the Biovisco studyY Henrotin, X Chevalier, M Deberg, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|September 24, 2013
Microbiological diagnosis of vertebral osteomyelitis: relevance of second percutaneous biopsy following initial negative biopsy and limited yield of post-biopsy blood culturesG Gras, R Buzele, J J Parienti, et al.
Seminars in Arthritis and Rheumatism|January 9, 2007
Optimal duration of antibiotic therapy in vertebral osteomyelitisF Roblot, J M Besnier, L Juhel, et al.
Annals of the Rheumatic Diseases|May 13, 2014
Adalimumab in patients with hand osteoarthritis refractory to analgesics and NSAIDs: a randomised, multicentre, double-blind, placebo-controlled trialX Chevalier, P Ravaud, E Maheu, et al.
Clinical and Experimental Immunology|May 12, 2015
Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortiumB Rup, M Pallardy, D Sikkema, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Scandinavian Journal of Rheumatology|February 6, 2010
Trough infliximab concentration may predict long-term maintenance of infliximab in ankylosing spondylitisD Chu Miow Lin, D Mulleman, N Azzopardi, et al.
Scandinavian Journal of Rheumatology|April 22, 2016
Diagnostic delay of pyogenic vertebral osteomyelitis and its associated factorsM Jean, J-O Irisson, G Gras, et al.
Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society|February 21, 2013
Early decrease of serum biomarkers of type II collagen degradation (Coll2-1) and joint inflammation (Coll2-1 NO₂ ) by hyaluronic acid intra-articular injections in patients with knee osteoarthritis: a research study part of the Biovisco studyY Henrotin, X Chevalier, M Deberg, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|September 24, 2013
Microbiological diagnosis of vertebral osteomyelitis: relevance of second percutaneous biopsy following initial negative biopsy and limited yield of post-biopsy blood culturesG Gras, R Buzele, J J Parienti, et al.
Seminars in Arthritis and Rheumatism|January 9, 2007
Optimal duration of antibiotic therapy in vertebral osteomyelitisF Roblot, J M Besnier, L Juhel, et al.
Annals of the Rheumatic Diseases|May 13, 2014
Adalimumab in patients with hand osteoarthritis refractory to analgesics and NSAIDs: a randomised, multicentre, double-blind, placebo-controlled trialX Chevalier, P Ravaud, E Maheu, et al.
Clinical and Experimental Immunology|May 12, 2015
Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortiumB Rup, M Pallardy, D Sikkema, et al.
Pageof 2